Tyloxapol

CAS No. 25301-02-4

Tyloxapol( —— )

Catalog No. M13750 CAS No. 25301-02-4

Tyloxapol is a non-ionic detergent often used as a surfactant.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG 28 In Stock
500MG 41 In Stock
1G 49 In Stock

Biological Information

  • Product Name
    Tyloxapol
  • Note
    Research use only, not for human use.
  • Brief Description
    Tyloxapol is a non-ionic detergent often used as a surfactant.
  • Description
    Tyloxapol is a non-ionic detergent often used as a surfactant.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Twenty-one adult male Wistar rats, aged 11–12 weeks weighing 180-200 g.Dosage:50 mg/kg.Administration:Injected intraperitoneally, BW, every other day.Result:Caused a significant (P?< 0.05) elevation in the levels of TBARS combined with an inhibition of the antioxidant enzymes (GPx, GST, CAT, SOD) in rat plasma, liver, and brain.Induced DNA fragmentation and inhibited the activities of acetylcholinesterase and mono aminoxidase in the brain.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    NF-κB
  • Recptor
    NF-κB| LPL
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    25301-02-4
  • Formula Weight
    137.18
  • Molecular Formula
    C70H124O13
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    NCCC1=CC=C(O)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Levine S, Saltzman A. J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):224-6.
molnova catalog
related products
  • Aurantiamide

    Aurantiamide has anti-cancer anti-inflammatory and antinociceptive activities it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB JNK and p38 pathways.

  • Iguratimod

    A novel disease-modifying antirheumatic drug that inhibits NF-kappaB (NF-κB) p65 subunit (RelA) phosphorylation and nuclear translocation without affecting IKBα degradation.

  • Ginsenoside Rb1

    Ginsenoside Rb1 is part of a class of steroid glycosides; may have properties that inhibit or prevent the growth of tumors.